(Q27853311)

English

Osimertinib: First Global Approval

scientific article

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

1 reference

PubMed publication ID

26729184

retrieved

13 November 2016

title

Osimertinib: First Global Approval (English)

1 reference

stated in

PubMed

PubMed publication ID

13 November 2016

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Sarah L Greig

1

0 references

publication date

February 2016

0 references

published in

Drugs

0 references

volume

76

0 references

issue

2

0 references

page(s)

263-73

0 references

cites work

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-015-0533-4

retrieved

21 January 2018

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26729184

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

(Q27853311)

Osimertinib: First Global Approval

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)